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Tissue-engineered vascular microphysiological 
platform to study immune modulation of  
xenograft rejection
Tae Hee Kim1†, Ji-Jing Yan2†, Joon Young Jang2, Gwang-Min Lee2,3, Sun-Kyung Lee2,3,  
Beom Seok Kim4, Justin J. Chung1, Soo Hyun Kim1, Youngmee Jung1,5*, Jaeseok Yang2,6*
Most of the vascular platforms currently being studied are lab-on-a-chip types that mimic capillary networks and 
are applied for vascular response analysis in vitro. However, these platforms have a limitation in clearly assessing 
the physiological phenomena of native blood vessels compared to in vivo evaluation. Here, we developed a simply 
fabricable tissue-engineered vascular microphysiological platform (TEVMP) with a three-dimensional (3D) vascu-
lar structure similar to an artery that can be applied for ex vivo and in vivo evaluation. Furthermore, we applied 
the TEVMP as ex vivo and in vivo screening systems to evaluate the effect of human CD200 (hCD200) overexpres-
sion in porcine endothelial cells (PECs) on vascular xenogeneic immune responses. These screening systems, in 
contrast to 2D in vitro and cellular xenotransplantation in vivo models, clearly demonstrated that hCD200 over-
expression effectively suppressed vascular xenograft rejection. The TEVMP has a high potential as a platform to 
assess various vascular-related responses.
INTRODUCTION
Various tissue-engineered microphysiological platforms, which in-
clude organs-on-chips and organ replicas, have been studied for 
application in basic, pharmaceutical and medical sciences as simple 
and rapid investigation tools (1). In particular, since blood vessels 
are related to various fundamental physiological phenomena, in-
cluding immune responses and human diseases, there is a great 
need to develop a vascular platform for research on them (2). Most 
of the currently developed vascular platforms are vessel-on-a-chip 
types and are applied as in vitro vascular disease models, vascula-
ture in organ-on-chips, and drug screening platforms by mimicking 
capillary networks through angiogenesis or vasculogenesis (3–6). 
Yasotharan et al. (7) proposed an artery-on a-chip that can evaluate 
the calcium dynamic response to abluminal stimulation. In most 
cases, these vascular platforms fabricated a randomly formed 
capillary-like vascular structure through the self-assembly of endo-
thelial cells (ECs) in hydrogels or were manufactured by coating ECs 
on the channel wall of a chip composed of synthetic polymers (e.g., 
polydimethylsiloxane), which is mechanically and physiologically 
different from the native vessel. These are useful tools for simply 
evaluating the physiological phenomena of blood vessels in vitro, 
but they have some limitations in clearly analyzing the physiologi-
cal phenomena of native blood vessels, such as in vivo assessment. 
To compensate for these limitations, we fabricated a tissue-engineered 
vascular microphysiological platform (TEVMP), which can be applied 
not only in  vitro but also in  vivo, with a three-dimensional (3D) 
vascular structure similar to an artery.
Tissue-engineered vascular graft (TEVG) studies have been con-
ducted in various ways for a long time (8). Many studies have fabri-
cated TEVGs using biodegradable synthetic polymers (e.g., 
polyglycolic acid, polylactic acid, and polycaprolactone) or alloge-
neic and xenogeneic decellularized tissues as materials for consti-
tuting TEVG scaffolds. These scaffolds were additionally treated 
with various natural components, such as collagen and fibrin, to 
induce vascular cell adhesion and differentiation. Furthermore, in 
these scaffolds, mural cells (e.g., vascular smooth muscle cells, fibro-
blasts, and pericytes) and ECs were cocultured to mimic mature 
blood vessels (9). However, the intended application of most TEVG 
studies has been to provide vascular replacements for clinical vascu-
lar implantation. The corresponding fabrication processes are com-
plex and time consuming. For these reasons, it is inefficient to apply 
these TEVG fabrication processes as vascular screening platforms. 
The TEVMP developed in this study was designed to be fabricated 
quickly using a simple process to apply a TEVG as a vascular screen-
ing tool. TEVMP was fabricated through a simple plastic compres-
sion process using collagen and fibrin hydrogels, which are the 
main components of the extracellular matrix (ECM) that compose 
blood vessels. The greatest shortcoming of hydrogel scaffolds is 
their weak mechanical properties. The plastic compression process 
allows a notable and rapid increase in the scaffold strength, as it 
removes water from the hydrogels and increases their density (10). 
Unlike previous studies that introduced dense scaffolds fabricated 
with either collagen or fibrin hydrogels by the same principle and 
method (11, 12), collagen-fibrin hybrid gels were used in this study. 
Scaffolds fabricated using only collagen or fibrin hydrogels are dif-
ficult to use as vascular structures because of their low elasticity or 
stiffness, even when plastic compression is introduced (13). There-
fore, hybrid gels containing collagen, which increases stiffness, and 
fibrin, which increases elasticity, were used, and a plastic compres-
sion process was introduced to improve the mechanical properties 
of the TEVMP.
Organ transplantation is the treatment of choice for patients with 
end-stage organ failure; however, organ shortage is an important 
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hurdle. Xenotransplantation could be a potential alternative to mit-
igate aggravating discrepancies between organ needs and organ 
supply. Because immune rejection in xenografts is much stronger 
than that in human allografts, xenograft rejection remains the main 
hurdle to successful clinical application, and we need to develop 
better immune modulation strategies to suppress xenograft rejec-
tion. One of the strategies to suppress xenograft rejection is the 
genetic modification of donor pigs that could reduce systemic 
immunosuppression to avoid heavy immunosuppression-related 
adverse events. The successful introduction of 1,3-galactosyltrans-
ferase gene-knockout pigs (14) and human complement regulatory 
protein-transgenic pigs such as hCD46-transgenic pigs (15) could 
avoid catastrophic hyperacute rejection and prolong xenograft sur-
vival (16); however, acute vascular rejection remains a challenge to 
be overcome (14, 17, 18). CD200 is a well-known inhibitory mole-
cule that suppresses macrophages and antigen-presenting cells as 
well as T cells, which are involved in acute vascular xenograft rejec-
tion (19–21). Previous studies have reported that CD200 suppresses 
rat-to-mouse cellular xenograft rejection and cellular allograft re-
jection (22, 23). Furthermore, our previous study demonstrated 
that overexpression of human CD200 (hCD200) in porcine ECs 
(PECs) showed the best suppressive effects against acute cellular 
xenograft rejection compared to overexpression of human CD47 
(hCD47) through in vitro and cellular xenotransplantation using a 
humanized mouse model (24). However, these studies showed ben-
eficial effects of CD200 for suppressing only cellular rejection in 
cellular xenotransplantation models. They could not demonstrate 
the impact of hCD200 overexpression on vascular rejection, which 
is a stronger rejection than cellular rejection and a key obstacle to 
successful organ xenotransplantation (25).
There remain some challenges with introducing hCD200 into 
transgenic pigs to test the beneficial effects of hCD200 overexpres-
sion on vascular xenograft rejection. Since the generation of trans-
genic pigs requires complicated processes, a long time, and high 
cost, before generation, more convenient screening tests targeting 
vascular xenograft rejection should be performed in a human micro-
environment using native tissue-like 3D platforms. The TEVMP 
could be a potential alternative, mimicking the human vascular sys-
tem for testing the effects of hCD200. In this study, we applied the 
TEVMP as an ex vivo and in vivo screening tool as a bioartificial blood 
vessel mimicking the native blood vessels of hCD200-transgenic 
pigs to evaluate the effect of hCD200 on vascular xenograft rejec-
tion in the human circulatory system–like microenvironment.
The overall study scheme from the generation of TEVMPs for 
ex vivo and in vivo functional studies is shown in Fig. 1. PECs that 
overexpress hCD200 or hCD47 were injected into the lumen of 
TEVMPs to endothelialize TEVMPs with PECs (pTEVMPs) as an 
alternative to the blood vessels of transgenic pigs. After that, the 
pTEVMP was applied to an ex vivo screening system, where human 
whole blood was perfused into the pTEVMP through the microflu-
idic system, and an in vivo screening system, where the pTEVMP 
xenograft was transplanted into humanized mice, to investigate the 
immune regulatory roles of hCD200 and hCD47 against vascular 
xenograft rejection. We proved the promising roles of this pTEVMP 
not only as an ex vivo vascular platform but also as an in vivo vascu-
lar platform in vascular xenotransplantation to humanized mice 
and found that overexpression of hCD200 in PECs successfully sup-




Physiologically and mechanically stable TEVMPs are produced 
through the following series of processes (Fig. 2A): A 1-ml syringe 
with a rod inserted in the center was loaded with a collagen-fibrin 
hybrid solution to form a structure that mimics the vascular lumen. 
After gelation of the hybrid solution, a high-density compression 
TEVMP was fabricated through a modified plastic compression 
technique. The fabricated TEVMPs were mounted in custom-made 
vascular perfusion chambers, and suspended PECs were injected 
into the lumen of the TEVMPs for endothelialization. Thereafter, 
pTEVMPs were connected to the microfluidic system, and the cul-
ture media of PECs were perfused into the lumen of pTEVMPs 
under physiological blood flow conditions for 1 day. Figure 2B shows 
the forms of the TEVMP before and after plastic compression. The 
external diameter of the TEVMP decreased from 5.11 ± 0.10 mm to 
1.53 ± 0.02 mm after plastic compression, while the inner diameters 
were 819 and 815.99 ± 54.64 m before and after compression, re-
spectively, showing similar values.
The mechanical strength and stability of the pTEVMP
To evaluate the mechanical properties of the TEVMP, burst pres-
sure and tensile testing were performed in three groups (Fig. 2C): 
the TEVMP fabricated by collagen with plastic compression 
(Col-PC group), the TEVMP fabricated by collagen-fibrin hybrid 
gels without plastic compression (Hybrid group), and the TEVMP 
fabricated by collagen-fibrin hybrid gels with plastic compression 
(Hybrid-PC group). The Hybrid-PC group showed a high burst 
pressure value that was approximately two times higher than that of 
Fig. 1. Overall schematic illustration of the study. The overall study scheme 
from the generation of pTEVMPs to ex vivo and in vivo functional studies is illus-
trated. TEVMPs were fabricated via plastic compression and endothelialized with 
hCD200- or hCD47-overexpressing PECs. Using these pTEVMPs, the roles of hCD200 
and hCD47 in PECs were evaluated in an ex vivo circulation system and in vivo vas-
cular xenotransplantation to humanized mice as screening systems.
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the Col-PC group and approximately 1.4 times higher than that of 
the Hybrid group. The tensile testing of the Hybrid-PC group 
TEVMP was determined by using a universal testing machine, and 
three values (strain at break, strength at break, and Young’s modulus) 
were obtained and compared to those of the Col-PC and Hybrid 
groups. The tensile strain and strength at break for the Hybrid-PC 
group were significantly higher than those of the Hybrid group and 
Col-PC group (P < 0.01). For the Hybrid group, the tensile strain 
Fig. 2. Generation and characterization of the pTEVMP. (A) Process of the TEVMP fabrication and endothelialization with genetically engineered PECs. The TEVMP was 
fabricated by a modified plastic compression process of collagen-fibrin hybrid gels. hCD200-, hCD47-, or hCD200/CD47-overexpressing PECs as well as control PECs with 
mock vector were seeded into the lumen of TEVMPs to make pTEVMPs. (B) TEVMPs before (top) and after (bottom) compression. The inset shows a cross view of the 
TEVMP. Scale bars, 500 m. (C) Mechanical properties of the TEVMP, including the burst pressure, tensile strain, and Young’s modulus. Data are expressed as the 
means ± SEM. *P < 0.05 and **P < 0.01 compared to the collagen group, and #P < 0.05 and ##P < 0.01 compared to the Hybrid-PC group. (D) Cross-sectional SEM image of 
collagen with plastic compression, hybrid gels without plastic compression, and hybrid gels with plastic compression. Scale bars, 5 m. (E) Cross-sectional rhodamine 
phalloidin staining of pTEVMPs after perfusing PECs for 1 day. Rhodmine phalloidin is red and DAPI is blue. The white dotted contour indicates the pTEVMP outline. Scale bar, 
200 m. The inset shows a magnification of the pTEVMP cross-sectional wall. Scale bar, 20 m (F) Representative immunofluorescence images of intracellular junction proteins, 
including CD31 (green) and ZO-1 (red), in the lumen of pTEVMPs after perfusion for 1 day. Scale bars, 50 m. (G) A LIVE/DEAD assay for PECs in the lumen of pTEVMPs was performed 
using calcein AM (green) and EthD-1 (red) staining. Scale bars, 50 m. (H) Quantification of the cell viability in the pTEVMP lumen in the static and perfusion groups.
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was higher than that of the Col-PC group (P < 0.05), but the tensile 
strength was not significantly different from that of the Col-PC 
group (P  =  0.32). The examination of Young’s modulus revealed 
that the highest value was in the Col-PC group, followed by the 
Hybrid-PC group and Hybrid group (4.89 ± 0.18 kPa in the Col-PC 
group, 1.26 ± 0.058 kPa in the Hybrid group, and 3.09 ± 0.30 kPa in 
the Hybrid-PC group). Together, these mechanical property results 
indicate that the TEVMP of the Hybrid-PC group has the highest 
elasticity among the three groups and higher stiffness than that of 
the Hybrid group TEVMP. Figure  2D shows the cross-sectional 
surface morphology of each group of hydrogels analyzed by scan-
ning electron microscopy. The Col-PC group fabricated by colla-
gen formed bundles of fibers of uniform thickness, but the Hybrid 
and Hybrid-PC groups fabricated by hybrid gels were formed by 
mixing thin and thick fibers. In the Col-PC and Hybrid-PC groups 
subjected to plastic compression, the fibers were arranged in a lay-
ered structure, whereas in the Hybrid group, the fibers showed a 
loose net structure.
The distributions of PECs, intercellular junctions, and viability 
were investigated to confirm the effect of the shear stress generated 
during perfusion with physiological blood flow conditions on the 
PECs endothelialized in TEVMPs. In the cross-sectional image, 
F-actin stained with phalloidin was expressed throughout the lu-
men of pTEVMPs perfused for 1 day, indicating that PECs were not 
detached by shear stress and were evenly distributed throughout the 
vessel wall of TEVMPs (Fig. 2E). Figure 2F shows that intercellular 
junction markers, such as cluster of differentiation 31 (CD31) and 
zonula occludens-1 (ZO-1), were expressed uniformly and continu-
ously at the cell-cell edges of the pTEVMP lumen surface. More-
over, in perfused pTEVMPs, the viability of PECs was 96.28 ± 0.57%, 
which was similar to that of PECs cultured under static conditions 
(96.11 ± 0.57%) (Fig. 2, G and F). These results indicate that PECs 
formed a stabilized endothelium through the high cell adhesion 
ratio and formation of intercellular junctions in the lumen of the 
TEVMP, and thus, the pTEVMP could be used as an artificial 
vascular platform in the physiological blood flow environment.
Impact of hCD200 in PECs on in vitro immune responses
PECs were transduced with lentiviruses containing the mock vec-
tor, hCD47, hCD200, or both hCD200 and hCD47 to overexpress 
hCD200 or hCD47. In the coculture of PECs and human peripheral 
blood mononuclear cells (hPBMCs) in the presence of human plas-
ma (Fig.  3A), both hCD200 and hCD47  in PECs suppressed the 
phagocytic activity of hPBMCs against PECs (Fig. 3B). Next, hCD200 
in PECs suppressed apoptosis of PECs (annexin V+pCD31+) and 
increased the viability of PECs [7-aminoactinomycin D (7-AAD)−p-
CD31+] against the cytotoxic activity of hPBMCs (Fig. 3C). hCD200 in 
PECs also suppressed the levels of tumor necrosis factor– (TNF-), 
interleukin-1 (IL-1), and IL-6 (Fig. 3D). These results demon-
strate that the overexpression of hCD200 in PECs successfully sup-
pressed the xenogeneic immune response by human immune cells 
and xenoreactive antibodies.
Impact of hCD200 on ex vivo immune responses toward 
the pTEVMP
To assess the impact of the overexpression of hCD200 or hCD47 in 
PECs on xenogeneic immune responses, we established an ex vivo 
pTEVMP circulation system as follows: TEVMPs were endothelial-
ized with normal PECs (control group), hCD47-overexpressing 
PECs (CD47 group), hCD200-overexpressing PECs (CD200 group), 
and hCD200/hCD47-overexpressing PECs (double group) and perfused 
with PBMCs or human whole blood as physiological blood flow.
When hPBMCs and human plasma were perfused through 
pTEVMPs, hCD200 in PECs suppressed xenogeneic immune re-
sponses in the pTEMVP circulation system (fig. S1). The survival of 
PECs was estimated by flow cytometry analysis of porcine CD31 
(pCD31; fig. S1A). The number of surviving PECs was higher in the 
CD200 and double groups than in the control group, while the 
CD47 group showed no significant difference from the control 
group. To confirm the interactions between PECs and human in-
flammatory cells, we evaluated immunofluorescence staining re-
sults for human CD68, a marker of macrophages, and human CD3, 
a marker of T cells (fig. S1B). In the CD200 group, both human 
CD68+ and CD3+ densities were approximately 5 and 17 times lower 
than those of the control group, respectively (fig. S1B). In particu-
lar, the human CD3+ cell density of the CD200 group was remark-
ably lower than that of the CD47 group and the double group 
(P  <  0.01). In addition, analysis of the perfusate obtained by the 
perfusion of hPBMCs and human plasma using the pTEVMP circu-
lation system was performed. Similar to the in vitro evaluation, the 
levels of TNF-, IL-1, and IL-6 were very low in the CD200 group 
compared to the control group (fig. S1C). The levels of complement 
components 3a (C3a) and 5a (C5a) in the perfusates were signifi-
cantly reduced in the CD200 group (Cont. versus CD200: P < 0.01; 
CD47 versus CD200: P < 0.05) (fig. S1D). In the case of the CD47 
group, C5a was remarkably decreased compared to the control 
group (P < 0.01), but C3a did not show a significant difference from 
the control group.
Next, human whole blood was perfused in each group of pTEVMPs 
to estimate vascular xenograft rejection ex vivo (Figs. 4 and 5). 
Apoptosis of PECs was determined using immunofluorescence 
staining of caspase 3 (Fig. 4A). The caspase 3+ cell density to the 
pCD31+ cells was the lowest in the CD200 group, followed by the 
double group, CD47 group, and, lastly, the control group (fig. S2A). 
In parallel, the number of 7-AAD−pCD31+ cells analyzed by flow 
cytometry was higher in the CD200 group than in the other three 
groups (Fig. 4B). The double group had a higher survival of PECs 
than the control group, and the CD47 group did not differ signifi-
cantly from the control group. These data indicate that hCD200 in 
PECs suppressed PEC apoptosis and improved PEC survival to a 
greater extent than hCD47 and the double overexpression of hCD200/
CD47. Figure 4C and fig. S2B indicate infiltration of human inflam-
matory cells and complement deposition in each group of pTEVMPs. 
CD68+ macrophage and CD3+ T cell densities showed significantly 
lower expression in the CD200 group than in the CD47 and double 
groups as well as the control group (P < 0.01). These results demon-
strated that hCD200 in PECs suppressed the infiltration of CD68+ 
macrophages and CD3+ T cells into the pTEVMP tissues to a great-
er extent than hCD47. Moreover, hCD200 in PECs showed better 
suppressive effects on the deposition of antibodies and complement 
in pTEVMP tissues than hCD47. Immunoglobulin G (IgG) is the 
most common type of antibody found in blood circulation, which is 
a major component of humoral immunity and activates all the clas-
sical pathways of the complement system (26). C4d is a marker of 
antibody-mediated rejection as a by-product of complement activa-
tion via the classic pathway by antibody-antigen complexes (27). 
The CD200 group significantly decreased the human IgG+ and 
C4d+ area density in the pTEVMP better than the control and CD47 
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groups (Cont. versus CD200: P < 0.01; CD47 versus CD200: P < 0.05), 
and the double group exhibited effects similar to those of the CD200 
group. When human cytokine levels in the perfusates were ana-
lyzed, hCD200 suppressed the levels of TNF-, IL-1, and IL-6, and 
there was no difference in the suppressive activity between the 
hCD200 and double groups (Fig. 4D). The levels of C3a and C5a in 
the perfusates were also significantly lower in the CD200 group 
than in the control and hCD47 groups (Fig. 4E). Overall, these data 
showed that hCD200 overexpression in PECs effectively suppressed 
human cellular and antibody-mediated xenogeneic immune re-
sponses against the pTEVMP.
We also investigated the impact of hCD200 overexpression in PECs 
on thrombocoagulation responses in response to xenogeneic stimula-
tion in an ex vivo pTEVMP circulation system. Scanning electron micro-
scope analysis showed human platelet to pTEVMP lumen surfaces 
in each group (Fig. 5A). In the CD200 group, platelets rarely adhered 
to the surface of the pTEVMP lumen surface, whereas the pTEVMP 
in the control group showed high platelet adhesion (red triangles), 
and the CD47 and double groups showed partial platelet adhesion. 
As a result of immunofluorescence staining analysis with CD41+ 
platelets and P-selectin (CD62P+), which is released and expressed 
on the cell surface upon platelet activation (28), the CD200 group 
showed the lowest CD41 platelet and P-selectin expression (Fig. 5B). 
In particular, P-selectin in the CD200 group was significantly de-
creased compared with that in the CD47 and double groups (P < 0.01) 
(fig. S3). These data indicate that hCD200 in PECs suppressed the 
adhesion and infiltration of human platelets on pTEVMP tissues 
better than hCD47 and double overexpression. Similar results were 
also confirmed by flow cytometry of the perfusate, in which platelet- 
monocyte aggregate formation was suppressed by hCD200 (Fig. 5C). 
Furthermore, hCD200 in PECs suppressed both tissue factor (TF) 
expression in monocytes (Fig. 5C) and TF levels in the perfusates of 
the ex vivo circulation system (Fig. 5D). The exposure of TF to the 
circulation triggers the initiation and propagation of highly coordi-
nated processes (29), and TF expression results from the activation 
of ECs in response to the deposition of xenoreactive antibodies and 
complement activation (30–32). Activated platelets may adhere to 
leukocytes and form circulating mixed aggregates, and their forma-
tion plays an important role in the initiation of thrombogenesis and 
inflammation (33). The levels of the thrombin-antithrombin complex 
Fig. 3. hCD200 suppressed in vitro xenogeneic immune responses by hPBMC in the presence of human plasma. (A) In vitro experimental scheme. After PECs were 
incubated with hPBMC with 20% human plasma, phagocytosis, cytotoxicity, and cytokine production were assessed. (B) Suppressive activity of hCD200 and hCD47 
against the phagocytic activity of hPBMC toward PECs. (C) Suppressive activity of hCD200 and hCD47 against apoptosis of PECs (annexin V+CD31+). Impact of hCD200 and 
hCD47 on live PECs (7-AAD−CD31+). (D) Suppressive activity of hCD200 and hCD47 against secretion of proinflammatory cytokines (TNF-, IL-1, and IL-6) from hPBMCs 
in response to PECs. n = 4 to 5 per group. Data are expressed as means ± SEM. *P < 0.05 and **P < 0.01 compared with the control group. #P < 0.05 compared with the 
CD200 group.
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(TAT), a marker for the activation of intravascular coagulation in 
the perfusates (34), were also suppressed by hCD200 (Fig. 5D). 
These results demonstrated that hCD200 overexpression in PECs 
effectively suppressed human thrombocoagulation responses by xe-
nogeneic immune responses against the pTEMVP. Together, the 
ex vivo pTEVMP circulation system could provide an efficient 
xenogeneic immune response platform that enables dynamic and 
mechanistic characterization of both cellular and humoral xeno-
geneic immune responses.
Impact of anti-CD200 treatment on the xenogeneic 
immune response
To demonstrate the suppressive effect of hCD200 on the xenogeneic 
immune response more clearly, hCD200-overexpressing PECs were 
treated with anti-hCD200, and xenogeneic immune responses were 
evaluated by an ex vivo pTEVMP circulation system and in vitro 
assays. In xenogeneic coculture of PECs and hPBMCs, anti-hCD200 
antibody abrogated the in vitro suppressive effects of hCD200 on 
phagocytosis (fig. S4A), apoptosis (annexin V+pCD31+) and cell 
death (7-AAD−pCD31+) (fig. S4B), and secretion of proinflammatory 
cytokines such as TNF-, IL-1, and IL-6 by PECs (fig. S4C).
In the ex vivo circulation system, while the CD200 group exhib-
ited decreased apoptosis of PECs (caspase 3+ cell density to pCD31+ 
cells), hCD200 in PECs blocked with anti-hCD200 (CD200 + Anti- 
CD200 group) increased apoptosis of PECs up to the level in the 
control group (Fig.  6A and fig. S5A). However, in control PECs, 
there was no significant difference between anti-hCD200 treatment 
(control + Anti-CD200 group) and nontreatment (control group). 
The survival of PECs also showed a similar tendency to that of 
apoptosis. The number of 7-AAD−pCD31+ cells was significantly 
higher in the CD200 group, and the number in the CD200 + 
Anti-CD200 group was similar to those in the control group and 
control + Anti-CD200 group (Fig.  6B). Next, anti-hCD200 anti-
body treatment attenuated the beneficial effects of hCD200 on in-
flammatory cell infiltration as well as the deposition of IgG and 
C4d (Fig. 6C). In the CD200 + Anti-CD200 group, the CD68+ 
macrophage and CD3+ T cell densities as well as human C4d+ and 
human IgG+ area densities of the pTEVMP lumen increased by ap-
proximately 5.9, 5.5, 2.9, and 4.9 times compared with that of the 
CD200 group, respectively (fig. S5B). Moreover, we confirmed that 
anti- hCD200 antibody treatment abrogated the beneficial ef-
fects of hCD200 on inflammation, thrombocoagulation, and com-
plement activation by xenogeneic immune responses. The beneficial 
effects of hCD200 overexpression in PECs on proinflammatory cy-
tokine production were abrogated by anti-hCD200 treatment. The 
CD200 + Anti-CD200 group showed significantly higher levels of 
TNF-, IL-1, and IL-6  in the perfusate than the CD200 group 
(P < 0.01 for TNF-; P < 0.05 for IL-1 and IL-6) (Fig. 6D). The 
levels of C3a, C5a, TF, and TAT, which were remarkably decreased 
in the CD200 group compared to the control group, showed no sig-
nificant difference among the CD200 + Anti-CD200 group, con-
trol group, and control + Anti-CD200 group (Fig.  6,  E  and  F). 
Fig. 4. hCD200 suppressed xenogeneic cytotoxicity and inflammation against the pTEVMP in the ex vivo circulation system of human whole blood. (A) Repre-
sentative immunofluorescence images for human CD31 (green) and caspase 3 (red) in PECs in the pTEVMP lumen of each group. Magnification, ×200. Scale bars, 50 m. 
(B) Flow cytometric analysis of the viability of PECs (annexin V/7-AAD) and absolute number of live PECs (7-AAD−CD31+) in pTEVMPs. (C) Representative immunofluores-
cence images for human CD68, CD3, IgG, C4d (red), and 4′,6-diamidino-2-phenylindole (DAPI) (blue) in the pTEVMP lumen of each group. Magnification, ×200. Scale bars, 
50 m. (D) Cytokine levels (TNF-, IL-1, and IL-6) in the perfusates. (E) Levels of C3a and C5a in the perfusates. n = 4 to 5 per group. Data are expressed as the means ± SEM. 
*P < 0.05 and **P < 0.01 compared with the control group. #P < 0.05 compared with the CD200 group.
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Overall, these results support that suppressing xenogeneic im-
mune responses in the CD200 group was mainly mediated by the 
overexpression of hCD200 in PECs.
Impact of hCD200 in PECs on pTEVMP xenograft 
survival in vivo
We confirmed the effect of hCD200 in PECs on the xenogeneic im-
mune responses in vivo by xenografting pTEVMPs into humanized 
mice for 4 hours. Humanized mice were prepared by the transfer of 
hPBMCs and human plasma (Fig.  7A). Engraftment of human 
CD45+ cells in the peripheral blood of humanized mice reached 
58.2%, and the levels of human IgG and IgM 1 day after the transfer 
of human plasma were significantly higher in humanized mice than 
in nonobese diabetic–severe combined immunodeficient IL-2Rg 
null (NSG) mice without transfer (fig. S6, A and B). In the pTEVMP 
xenotransplantation to humanized mouse model, no vascular oc-
clusion was noted at the anastomotic sites of the explanted xeno-
grafts (movie S1).
The in vivo xenogeneic immune response of hCD200 in PECs 
was similar to that of the ex vivo pTEVMP circulation system re-
sults. When thrombosis inside the vascular lumen of the pTEVMP 
xenografts was checked visually after explanting, thrombosis was 
prominent in the control group, whereas thrombosis was mild in 
the CD47, CD200, and double groups (Fig. 7B and fig. S7). Apopto-
sis of PECs (caspase 3+ cell density to pCD31+ cells) in the pTEVMP 
xenografts was decreased in the CD47, CD200, and double groups 
compared to the control group (Fig. 7C). In particular, the CD200 
group showed a caspase 3+ cell density that was 13.8 times lower 
than that of the CD47 group and 4.1 times lower than that of the 
double group, indicating that hCD200 in PECs has the greatest sup-
pressive effect on apoptosis of PECs (fig. S8A). The viability of PECs 
in the pTEVMP xenografts (number of 7-AAD-pCD31+ cells) was 
also significantly increased in the CD200 group compared to the 
control group (P < 0.01) and the CD47 group (P < 0.05) (Fig. 7D).
Next, hCD200 in PECs effectively suppressed the inflammatory 
cell infiltration and deposition of complement components in the 
pTEVMP xenografts. The CD68+ macrophage and CD3+ T cell 
densities and human C4d+ and human IgG+ area densities in the 
pTEVMP xenografts showed the lowest value in the CD200 group, 
followed by the double group, CD47 group, and control group 
(Fig. 8A and fig. S8B). When proinflammatory cytokine production 
was assessed using plasma collected from humanized mice xeno-
grafted with pTEVMPs, hCD200 in PECs of pTEVMP xenografts 
significantly suppressed plasma levels of TNF-, IL-1, and IL-6 
(Fig. 8B). Furthermore, the CD200 group significantly suppressed 
the plasma levels of C3a and C5a (Fig. 8C) as well as those of TF and 
TAT (Fig. 8D) after xenotransplantation; however, there was no 
additive effect in the CD47 group and double group compared to 
the CD200 group. These results suggest that the pTEVMP could be 
used as a tool to assess the in vivo xenogeneic immune response of 
hCD200 via vascular xenotransplantation.
DISCUSSION
The present study demonstrates that the pTEVMP, which can mim-
ic the microenvironment physiologically similar to native vessels in 
the human body, is successfully used to evaluate xenogeneic im-
mune responses in  vivo through a xenotransplantation model in 
humanized mice and ex vivo through a microfluidic system. Through 
this vascular platform, we demonstrated that overexpression of 
hCD200 in PECs can suppress human anti-pig xenogeneic immune 
responses and vascular xenograft rejection.
The TEVMP used in this study was fabricated simply through 
modified plastic compression using collagen-fibrin hybrid gels. 
Fibrin contained in hybrid gels is well known as an elastic polymer 
(35). For this reason, the vascular platform composed of hybrid gels 
had a higher tensile strain than the vascular platform composed of 
collagen. On the other hand, with regard to stiffness, the vascular 
Fig. 5. hCD200 suppressed xenogeneic thrombocoagulation responses against pTEVMP in the ex vivo circulation system of human whole blood. (A) Scanning 
electron microscopic images of the pTEVMP lumens in each group. Red triangles indicate platelets. Scale bars, 50 m. (B) Representative immunofluorescence images for 
human CD41, human CD62P (red), and DAPI (blue) in the lumen of pTEVMPs in each group. Scale bars, 50 m. (C) Platelet-monocyte aggregate formation (CD42b+CD14+ 
cells) and monocyte surface-bound TF expression (TF+CD14+ cells) in the xenoperfusate were measured using flow cytometry. (D) Levels of TF and TAT in the perfusates. 
n = 4 to 5 per group. Data are expressed as the means ± SEM. *P < 0.05 and **P < 0.01 compared with the control group. #P < 0.05 compared with the CD200 group.
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platform composed of hybrid gels was lower than that composed of 
collagen gels. Collagen gels form bundles of thicker collagen fibers 
with fibrils, while fibrin gels form a fine network of wispy fibers 
(36). Since the hybrid gels are a mixture of collagen and fibrin, they 
are expected to show lower stiffness than the vascular platform 
composed of pure collagen. Plastic compression greatly increases 
the strength of hydrogels by excluding water from the hydrogels to 
form dense hydrogels (10). In addition, filamentous protein polymers, 
such as collagen and fibrin, are stiffened in response to compression, 
shear, or tension (37). When plastic compression was performed on 
the vascular platform composed of hybrid gels (TEVMP), the stiffness 
and elasticity were greatly increased, and the improvement of these 
mechanical properties increased the burst pressure of the TEVMP. 
Moreover, since the hybrid gels that compose the TEVMP are the 
ECM components of blood vessels, they provide a microenviron-
ment similar to that of native vessels of PECs (38). Because of this, 
the adhesion of PECs was improved, and intercellular junction pro-
teins were uniformly expressed, resulting in stable endothelializa-
tion on the lumen side of TEVMPs.
We applied the TEVMP, which has such good mechanical and 
physiological properties, as an ex vivo and in vivo platform in the 
study of the role of hCD200  in vascular xenograft rejection. As a 
porcine bioartificial artery, the pTEVMP endothelialized with PECs 
made it possible to investigate the impact of hCD200 overexpression 
on vascular xenogeneic rejection and cellular xenogeneic rejection, 
which were not possible in in vitro analysis via an ex vivo microfluidic 
Fig. 6. Treatment with an inhibitory anti-CD200 antibody abrogated the beneficial effects of hCD200 in PECs on the xenogeneic immune responses against the 
pTEVMP in an ex vivo circulation system. (A) Representative immunofluorescence images for human CD31 (green) and caspase 3 (red) in PECs in the pTEVMP lumen of 
each group. Magnification, ×200. Scale bars, 50 m. (B) Flow cytometric analysis of the absolute number of live PECs (7-AAD−CD31+) in pTEVMPs. (C) Representative im-
munofluorescence images for human CD68, CD3, IgG, C4d (red), and DAPI (blue) in the pTEVMP lumen of each group. Magnification, ×200. Scale bars, 50 m. (D) Cytokine 
levels (TNF-, IL-1, and IL-6) in the perfusates. (E) Levels of C3a and C5a in the perfusates. (F) Levels of TF and TAT in the perfusates. n = 4 to 5 per group. Data are ex-
pressed as the means ± SEM. *P < 0.05 and **P < 0.01 compared with the control group. #P < 0.05 and ##P < 0.01 compared with the CD200 group.
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system mimicking the human circulation system. These microfluid-
ic systems to mimic physiological blood flow have been successfully 
used as screening tools before animal experiments (39, 40). In the 
ex vivo microfluidic system, hCD200 overexpression suppressed 
apoptosis of PECs, infiltration of T cells and macrophages into 
pTEVMPs, and arterial deposition of IgG and C4d. Consistent with 
these findings, the concentrations of C3a and C5a as well as pro-
inflammatory cytokines were decreased in the perfusate by over-
expression of hCD200. In addition, hCD200 overexpression decreased 
the infiltration of platelets into pTEVMPs, platelet-monocyte ag-
gregates, and the levels of TF and TAT in perfusates. These ex vivo 
assessment data more clearly demonstrated the effect of hCD200 on 
the xenogeneic immune response by showing that hCD200 overex-
pression suppressed xenogeneic antibody-mediated and thrombo-
coagulation responses toward vascular xenogeneic tissues as well as 
the xenogeneic cellular immune response, similar to in vitro analy-
sis. Furthermore, treatment with anti-CD200 blocking antibodies 
abrogated the beneficial effects of hCD200 overexpression on the 
suppression of the xenogeneic immune response, suggesting that 
beneficial effects in the hCD200 overexpression group were mainly 
mediated by overexpression of hCD200 in PECs of the pTEVMP.
Genetically modified pig to nonhuman primate xenotransplan-
tation models are the best preclinical xenotransplantation model, 
where acute vascular rejection and acute cellular rejection can occur. 
Fig. 7. hCD200 improved the survival of PECs in pTEVMP vascular xenografts in humanized mice. (A) Experimental scheme of pTEVMP xenotransplantation into 
humanized mice. (B) Gross findings of lumens of pTEVMP xenografts procured from humanized mice. “Original” indicates the pTEVMP before xenotransplantation. 
(C) Representative immunofluorescence images for human CD31 (green) and caspase 3 (red) in PECs in the lumen of pTEVMP xenografts. Magnification, ×200. Scale bars, 
50 m. (D) Flow cytometric analysis of the absolute number of live PECs (7-AAD−CD31+) in pTEVMP xenografts. n = 5 per group. Data are expressed as the means ± SEM. 
**P < 0.01 compared with the control group. ##P < 0.01 compared with the CD200 group.
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However, the high cost, rare source, and ethical dilemma of nonhu-
man primates led to low accessibility to research using this model, 
requiring a good screening animal model before final confirmation 
in nonhuman primate models. Recently, humanized mouse models 
have been successfully used for xenogeneic cell transplantation 
studies to study immune modulation strategies for acute cellular re-
jection (41, 42). A previous study that used PEC transplantation 
into humanized mice showed that overexpression of hCD200 sup-
pressed acute cellular xenograft rejection (24). However, this cellu-
lar xenotransplantation model cannot evaluate the impact of hCD200 
overexpression on antibody-mediated xenogeneic immune responses 
and thrombocoagulation responses toward vascular xenografts be-
yond cellular xenografts. Since the developed pTEVMP can be fab-
ricated to any desired size, we implanted the pTEVMP fabricated in 
a size that can be transplanted in humanized mice between the ab-
dominal aorta and inferior vena cava to evaluate the effect of 
hCD200 overexpression on vascular xenograft rejection in vivo. 
hCD200 overexpression suppressed apoptosis of PECs, perigraft in-
filtration of T cells and macrophages, and graft deposition of IgG 
and C4d in humanized mice in parallel with the results of ex vivo 
perfusion experiments. Plasma levels of proinflammatory cytokines, 
complement activation, and coagulation activation in humanized 
mice were also suppressed by hCD200 overexpression in vascular 
xenografts. These data suggest that hCD200 overexpression in vas-
cular xenografts suppresses vascular xenograft rejection, including 
xenogeneic antibody response, xenogeneic cellular response, and 
the activation of complement and coagulation systems.
CD200 has been shown to suppress phagocytic and cytotoxic ac-
tivity as well as the secretion of proinflammatory cytokines by mac-
rophages by binding to the CD200 receptor (24, 43). Moreover, CD200 
is reported to induce regulatory T cells and suppress antigen- 
presenting cells and T cells (44, 45). In parallel, using pTEVMP, this 
study showed that CD200 overexpression suppressed the perigraft 
infiltration of macrophages and T cells as well as suppressed TNF-, 
IL-1, and IL-6. B cells also express the CD200 receptor, and CD200 
can suppress antibody production after xenogeneic red blood cell 
sensitization (45, 46). However, it is unlikely that overexpression of 
hCD200 directly suppressed B cells or antibody-mediated xeno-
geneic immune responses for a short time in this study. We specu-
late that the decreased deposition of IgG and C4d in vascular 
xenografts in the hCD200 overexpression group might have been 
indirectly derived from the suppression of T cells and innate immu-
nity, such as macrophage activation, complement activation, and 
thrombocoagulation responses, against vascular xenografts.
Although hCD47 can suppress cellular xenograft rejection, such 
as hematopoietic cell, hepatocyte, and islet xenotransplantation, by 
suppressing macrophage activation by binding to CD172, the ben-
eficial effects of hCD47 overexpression in xenogeneic skin or heart 
transplantation were minimal, indicating that the roles of CD47 in 
xenografts are variable according to the cell types with hCD47 
Fig. 8. hCD200 suppressed xenogeneic immune responses against pTEVMP vascular xenografts in humanized mice. (A) Representative immunofluorescence im-
ages for human CD68, CD3, IgG, C4d (red), and DAPI (blue) in the lumen of pTEVMP xenografts. Magnification, ×200. Scale bars, 50 m. (B) Plasma cytokine levels (TNF-, 
IL-1, and IL-6) in humanized mice with pTEVMP xenografts. (C) Plasma levels of C3a and C5a in humanized mice with pTEVMP xenografts. (D) Plasma levels of TF and TAT 
in humanized mice with pTEVMP xenografts. n = 3 to 6 per group. Data are expressed as the means ± SEM. *P < 0.05 and **P < 0.01 compared with the control group. 
#P < 0.05 compared with the CD200 group.
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(47, 48). The interaction between CD47 and thromboplastin, another 
receptor of CD47, might stimulate vascular xenograft rejection and 
diminish the protective effects of hCD47 on xenotransplantation 
(49). In the present study, we demonstrated more clearly through 
ex vivo and in vivo analysis using the TEVMP that the beneficial 
effects of hCD47 overexpression on vascular xenograft rejection 
were weaker than those of hCD200 overexpression. There were no 
additive effects between hCD200 overexpression and hCD47 over-
expression on the suppression of xenogeneic immune responses 
against vascular xenografts, perhaps due to the overlapping actions 
of both molecules in macrophage suppression or the immune stim-
ulatory effects of CD47 via thromboplastin.
Together, these data suggest that this study is very meaningful in 
two respects: (i) The TEVMP developed in this study can be applied 
to various vascular-related studies and used not only as an ex vivo 
platform by simulating in vivo a physiological environment similar 
to the circulatory system but also as an in vivo platform by implant-
ing blood vessels into animals because of its high mechanical prop-
erties; and (ii) hCD200 has great potential for development into 
hCD200-transgenic pigs for organ xenotransplantation because of 
its superior suppressive effects on vascular xenograft rejection, be-
yond cellular xenograft rejection, compared with hCD47 that previ-
ous studies have established as an essential component of optimal 
genetically engineered pigs (50).
Furthermore, the next step in this study is to carry out research 
to overcome some limitations of the current platform. This vascular 
platform has a lower burst pressure than the arterial blood pressure 
of mice with higher blood pressure and faster heart rate compared 
to humans because of the absence of a tunica media layer composed 
of vascular smooth muscle cells in the arterial wall (51). Therefore, 
the pTEVMP was implanted between the abdominal aorta and infe-
rior vena cava of humanized mice as an aortocaval shunt for in vivo 
evaluation. The aortocaval shunt developed high vascular flow and 
caused heart failure in the recipient. For this reason, long-term 
in vivo evaluation was not possible in this study. Aortic xenografts 
instead of aortocaval shunt xenografts could avoid this complica-
tion. To overcome these obstacles, future research plans include 
adding a tunica media layer using stromal cells to improve the me-
chanical strength of the vascular platform enough to withstand 
small animals’ arterial blood pressure. The tunica media layer is a 
layer of smooth muscle (52). To mimic the smooth muscle layer in 
future research, we will need to add a layer including mesenchymal 
stem cells that can differentiate into smooth muscle cells in a hydrogel- 
based material with mechanical and physiological properties 
similar to those of the tunica media layer. Another limitation is that 
hPBMCs and plasma-based humanized mice are also not ideal for 
evaluating acute vascular xenograft rejection and chronic rejection 
because human hematopoiesis is not ongoing and there is a risk of 
graft-versus-host disease. Nevertheless, the pTEVMP has made it 
possible to simply and clearly investigate vascular xenograft rejec-
tion in vivo as well as ex vivo, and hPBMCs and plasma-based hu-
manized mice are easy and convenient models as screening test for 
studying vascular xenograft rejection.
In summary, in this study, we developed the TEVMP, for appli-
cation as an ex vivo and in vivo vascular platform to investigate the 
effect of hCD200 on the xenogeneic immune response. The TEVMP, 
fabricated by plastic compression using collagen-fibrin hybrid gels, 
which is an ECM component of blood vessels, can simply mimic 
native blood vessels due to its sufficient mechanical properties and 
stable 3D endothelialization. The TEVMP endothelialized with 
hCD200-overexpressing PECs could play a role similar to blood 
vessels of hCD200-transgenic pigs. pTEVMPs overexpressing hCD200 
were introduced for ex vivo evaluation using a whole-blood micro-
fluidic system and in vivo evaluation via xenotransplantation into 
humanized mice. In these evaluations, the survival of PECs, infiltra-
tion of human inflammatory cells, complement behavior, and 
thrombocoagulation responses were analyzed. It is noteworthy that 
in this evaluation using pTEVMP, it is possible to analyze vascular 
xenograft rejection, including thrombocoagulation responses that 
cannot be evaluated in 2D in vitro analysis or cellular xenotrans-
plantation models. We clearly demonstrated ex vivo and in vivo 
that overexpression of hCD200 improves the survival of PECs and 
effectively suppresses the infiltration of human inflammatory cells, 
complement activation, and thrombocoagulation responses to a 
greater extent than overexpression of hCD47. On the basis of these 
results, we suggest that the TEVMP has a high potential as a plat-
form to assess various vascular-related responses and that over-
expression of hCD200 in donor pigs could be a promising strategy 
for suppressing vascular xenograft rejection.
MATERIALS AND METHODS
Preparation of the pTEVMP
A schematic of the TEVMP is presented in Fig. 1. TEVMPs were 
fabricated by modifying the plastic compression technique of colla-
gen hydrogels to increase its mechanical properties, including elas-
ticity (53). Rat tail collagen I (8.21 mg/ml; Corning) was diluted to 
5 mg/ml using 10× phosphate-buffered saline (PBS; Gibco) and de-
ionized water (DW), and the pH was raised to 7.0 using 1 N of sodium 
hydroxide (Sigma-Aldrich). To increase the elasticity, a hybrid solution 
mixed with fibrinogen solution (5 mg/ml in PBS; Sigma-Aldrich) 
and collagen solution in a 1:1 ratio was prepared. The hybrid solution 
was mixed with thrombin (50 U/ml; Sigma-Aldrich) at a volume 
ratio of 50:1 and then immediately transferred to a 1-ml syringe 
with a closed three-way Luer-Lock stopcock attached. A 21-gauge 
spinal needle stylet (diameter, 819 m) was inserted in the center of 
the syringe and held in place with parafilm to create the TEVMP 
lumen. The hybrid solution loaded in the syringe was allowed to gel 
for 30 min at 37°C. After gelation of the hybrid solution, the hybrid 
gel with the inserted spinal needle stylet was taken out of the 1-ml 
syringe and laid onto a 0.8-m membrane filter placed on 10 Kim-
wipes. The Kimwipes were folded in half, wrapped around the hybrid 
gel, and hung for approximately 2 min to remove water from the 
hybrid gel. Then, the hybrid gel was flipped so that the top side faced 
downward. The process was repeated to form TEVMPs with a uniform 
wall thickness of high-density gels. The TEVMPs were immersed 
in PEC media and allowed to stabilize in a 37°C incubator for 1 day.
To endothelialize TEVMPs with PECs, the fabricated TEVMPs 
were mounted in custom-made vascular perfusion chambers and 
sutured in place using 3-0 black silk sutures. After injecting PEC at 
a concentration of 1.5 × 107 cells/ml into the lumen of the TEVMP, 
the chamber was sealed and rotated at 37°C for 2 hours on a custom 
rotating platform at 10 rotations per hour to allow cell adhesion.
Characterization of the pTEVMP
To analyze the burst pressure, TEVMPs were loaded in perfusion 
chambers with one end plugged and the other attached to a differential 
pressure gauge. The burst pressure was measured by pressurizing 
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the TEVMP with PBS manually until rupture. The tensile properties 
of the TEVMP were measured by a universal testing machine (Instron 
5966) at a 10-N load cell number and a crosshead speed of 10 mm/min 
(n = 4 per group). The tensile strength, elongation at break, and Young’s 
modulus were obtained from the stress-strain curves. The cross- 
sectional surface morphologies of hydrogels were characterized by 
Scanning Electron Microscope (Inspect F, FEI, OR, USA) following 
Pt coating using a sputter coater.
Endothelialization in the pTEVMP lumen was analyzed using 
immunofluorescence staining. The TEVMPs endothelialized with 
PECs were fixed overnight in 4% paraformaldehyde (3 M) at 4°C 
and washed with PBS. The pTEVMPs were then permeabilized in 
0.3% Triton X-100 (BIOSESANG) in PBS for 10 min and treated 
with blocking solution consisting of 4% bovine serum albumin 
(Sigma-Aldrich) dissolved in PBS for 1 hour. After that, anti-CD31 
(1:25; Abcam) and anti–ZO-1 antibodies (1:50; Invitrogen) were 
added to confirm EC intercellular junctions and incubated at 4°C 
overnight. Thereafter, secondary antibody, Alexa Fluor 488 (1:500; 
Abcam), was added for 2 hours and washed with PBS. The samples were 
mounted using VECTASHIELD with 4′,6-diamidino-2-phenylindole 
(DAPI; Vector Labs). A LIVE/DEAD assay for PECs in the lumen of 
pTEVMPs was performed using calcein AM (1:2000; Invitrogen) 
and EthD-1 (1:500; Invitrogen) staining under static and perfused 
culture conditions for 1 day. Images were acquired using a laser 
scanning confocal microscope (Zeiss LSM700).
Preparation of PECs and human blood
Lentiviruses containing mock (pLenti6-CMV2-Flag), hCD200- 
expressing (pLenti6-Flag-CD200), or hCD47-expressing (pLenti6-
Flag-CD47) vectors were produced by transient cotransfection with a 
three-plasmid system, as previously described (24). The control, hCD47- 
overexpressing, hCD200-overexpressing, and double (hCD200/
hCD47)–overexpressing PEC lines were established by transduc-
tion of lentivirus containing each target molecule into PECs, as pre-
viously described (24). Human fresh whole blood was extracted 
from healthy volunteers, and hPBMCs were isolated from human 
whole blood using Ficoll-Hypaque (GE-Healthcare) density gradi-
ent separation. The study was approved by the Institutional Review 
Board (H-1411-020-623) of the Seoul National University Hospital.
In vitro phagocytosis, cytotoxicity, and cytokine assay
Transduced PECs and hPBMCs were stained with Violet CellTracker 
(Thermo Fisher Scientific) and carboxyfluorescein succinimidyl 
ester (CFSE; Thermo Fisher Scientific), respectively. Labeled PECs 
(2 × 105 per well) were incubated with labeled hPBMCs (4 × 105 per 
well) in 96-well plates. The proportion of CFSE/violet double-positive 
cells among the CFSE PBMCs was analyzed by flow cytometry to 
evaluate phagocytic function after 2 hours. After 6 hours, the cell 
mixtures were analyzed for viability by flow cytometric analysis after 
simultaneous staining with annexin V and 7-AAD (BD Biosciences, 
San Diego, CA). The levels of cytokine secretion were measured in 
the supernatant using an enzyme-linked immunosorbent assay 
(ELISA) kit after the coculture of PECs and hPBMCs for 48 hours. 
To inhibit hCD200, cocultured cells were incubated with inhibitory 
anti-CD200 antibody (5 mg/ml; BD Biosciences).
Ex vivo microfluidic system
The TEVMPs were endothelialized with control PECs with mock 
vector, hCD200-overexpressing PECs, hCD47-overexpressing PECs, 
and double (hCD47/hCD200)–overexpressing PECs. The microflu-
idic system consisted of custom-made vascular perfusion chambers, 
reservoirs, BioPharm Plus silicone tubing (Masterflex), and peri-
staltic pumps (Masterflex L/S 07522-30) that are used in various 
medical applications, including blood circulation (49). Fresh hu-
man whole blood was diluted twofold in Hank’s balanced salt solu-
tion and perfused into pTEVMPs through a microfluidic system 
under physiological blood pressure conditions (1 ml/min of flow 
rate, 10 dyne/cm2 of fluid shear stress, 37°C) for 4 hours. In another 
set of experiments, the pTEVMP circulatory system was pretreated 
with anti-CD200 antibody 1 hour before the perfusion of human 
whole blood.
Measurement of cytokines, complements, and coagulability
The levels of human cytokines such as TNF-, IL-, and IL-6 were 
measured by ELISA (BioLegend, San Diego, CA) according to the 
manufacturer’s instructions. The levels of C5a and C3a were deter-
mined using ELISA (BD Biosciences). The levels of TF and TAT 
complexes were measured by ELISA (Abcam, Cambridge, UK).
Preparation of humanized mice
NSG mice were obtained from the Jackson laboratory (Bar Harbor, 
ME) and bred and maintained in a specific pathogen–free facility. 
The animal use protocols were approved by the Institutional Animal 
Care and Use Committee of Seoul National University (SNU-
200306-5-1). The hPBMCs (2 × 107) were intravenously transferred 
to NSG mice, which received pooled human plasma (0.2 ml) a week 
after the transfer of hPBMCs (Fig. 7A).
pTEVMP xenotransplantation to humanized mice
After humanized mice were systemically heparinized (200 U/kg), 
pTEVMPs (with an internal diameter of 0.82 mm, 3 cm long) were 
implanted into the humanized mice as interpositional grafts be-
tween the abdominal aorta and inferior vena cava by side-to-side 
anastomosis using 10-0 Prolene. The pTEVMP xenografts were 
procured at 5 hours after transplantation.
Flow cytometric analysis
The pTEVMP tissues were cut into small fragments and then di-
gested with frequent mixing for 20 min at 37°C in PBS containing 
fetal bovine serum (2%), EDTA (2.5 mM), collagenase type II (1 mg/ml; 
Sigma-Aldrich), and papain (10 mg/ml; Sigma-Aldrich). Cells were 
recovered from the digest by centrifugation and stained with 7-AAD 
(BD Bioscience) and the following antibodies: anti-pig CD31 (LCI-4, 
Bio-Rad, Hercules, CA), anti-human CD45 (HI30), anti-mouse 
CD45 (30-F11), and annexin V (BioLegend). Perfusates in the 
ex vivo pTEVMP circulation system were obtained after 5 hours of 
circulation and stained with the following antibodies: anti-human 
CD42b (HIPI, BioLegend), anti-human TF (NY2, BioLegend), and 
anti-human CD14 (61D3, Thermo Fisher Scientific). Each subset of 
cells was analyzed using an Attune NxT flow cytometer (Thermo 
Fisher Scientific) and FlowJo software (Tree Star, Ashland, OR).
Histological analysis
pTEVMPs were fixed in 4% paraformaldehyde for 24 hours at 4°C, 
embedded in an optimal cutting temperature compound (Leica), 
frozen using dry ice, and sectioned at a thickness of 30 m by using 
a cryomicrotome (CM3050 S, Leica). Sections were dried on slides, 
fixed in 4% paraformaldehyde for 30 min at 37°C, stained with 
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hematoxylin and eosin using standard protocols, and observed 
under a light microscope (Olympus).
Immunofluorescence staining was performed to assess the via-
bility of PECs, recruitment of human immune cells, and deposition 
of IgG and C4d. The following primary antibodies were used for 
staining: anti-pig CD31 (1:25; Abcam, Cambridge, UK), anti-human 
C4d (Millipore Sigma, St Louis, USA), anti–caspase 3 (1:50; 9H19 
L2, Thermo Fisher Scientific), anti-human CD3 (1:50; OKT3, Bio-
Legend), anti-human CD68 (1:100; Y1/82A, BioLegend), anti-human 
CD41 (1:25; HIP8, BioLegend), anti-human CD62P (1:100; AK4, 
BioLegend), and anti-human IgG (1:200; Bethyl Laboratories, Texas, 
USA). Next, secondary antibodies containing Alexa Fluor 488 or 
594 (1:500; Abcam) and DAPI were added. Images were acquired 
on a Zeiss LSM700 laser scanning confocal microscope (Carl Zeiss AG, 
Oberkochen, Germany). The ImageJ plugin (https://imagej.nih.gov) 
was used for cell counting, and the positive cells were measured by 
counting four high-power fields (200×) per section. The positive 
area densities were calculated as the ratio of the CD68+, CD3+, 
C41+, CD62P+, IgG+, and C4d+ areas to the total cell area. The 
caspase 3+ cell density was also calculated as the ratio of the caspase 
3+ area to the CD31+ area.
Statistical analysis
All data are presented as the means ± standard error of the means 
(SEM) and were analyzed by analysis of variance (ANOVA) with post 
hoc comparisons. P values less than 0.05 were considered statistically 
significant. Statistical analyses were performed using GraphPad 
Prism 7 software (GraphPad Software, La Jolla, CA).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/22/eabg2237/DC1
View/request a protocol for this paper from Bio-protocol.
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